• Positive data from azer-cel CAR T-cell therapy trial, with 4 out of 7 patients achieving Complete Responses
• Progress in onCARlytics and VAXINIA clinical trials for solid tumors
• Secured $46 million in funding through convertible notes and warrants
• Received $11.7 million R&D tax refund for 2023 financial year

Imugene Limited reported a loss of $48.3 million for the half-year ended 31 December 2024, a 30% reduction compared to the prior period. The decrease in loss was driven by a reduction in clinical trial and research costs. As of 31 December 2024, the company had cash reserves of $33.7 million, which increased to $65.4 million after accounting for a $11.7 million R&D tax refund and $20 million in convertible note proceeds received in January 2025.The company made significant progress in its clinical programs during the period. The azer-cel CAR T-cell therapy trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) continued to generate positive data, with 4 out of 7 patients in Cohort B achieving Complete Responses. The onCARlytics (OASIS) Phase 1 trial for solid tumors dosed its first patient in the intratumoural combination arm, while the MAST trial evaluating VAXINIA in biliary tract cancer saw one patient maintain a Complete Response for over two years.Imugene also secured a $46 million funding agreement with CVI Investments, including $20 million in convertible notes and up to $26 million from warrants. The company has implemented cost-saving initiatives to extend its cash runway to the end of 2025, excluding any further warrant exercises.

Imugene has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.

The announcement does not provide any specific forward-looking outlook statements.